Van DijkPR, GroenierKH, DeVriesJH, GansROB, KleefstraN, BiloHJG, LogtenbergSJJ: Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability. Diabetes Technol Ther, 2015; 17:379–384.
2.
CatargiB, MeyerL, MelkiV, RenardE, JeandidierN; EVADIAC Study Group: Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Diabetes Metab, 2002; 28:133–137.
3.
HaardtMJ, SelamJL, SlamaG, BethouxJP, DorangeC, MaceB, RamanicheML, BruzzoF: A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes. Diabetes Care, 1994; 17:847–851.
4.
SelamJL, RaccahD, Jean-DidierN, LozanoJL, WaxmanK, CharlesMA: Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care, 1992; 15:53–58.
5.
RodbardD: Clinical interpretation of indices of quality of glycemic control and glycemic variability. Postgrad Med, 2011; 123:107–118.
6.
RodbardD: Hypo- and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. Diabetes Technol Ther, 2012; 14:868–876.
7.
QuY, JacoberSJ, ZhangQ, WolkaLL, DeVriesJH: Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther, 2012; 14:1008–1012.
8.
MonnierL, WojtusciszynA, ColetteC, OwensD: The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther, 2011; 13:813–818.
9.
RodbardD: New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther, 2009; 11:551–65.
